Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Cell & Bioscience

Fig. 1

From: Brusatol, an NRF2 inhibitor for future cancer therapeutic

Fig. 1

Schematic illustration of brusatol anticancer effect by inhibiting NRF2 activity. NRF2 is the key transcription factor regulating oxidative homeostasis. In normal cells, NRF2 is recognized by KEAP1 for ubiquitination and degradation. Oxidative stress compromises the function of KEAP1, allowing the stabilization and transcriptional activity of NRF2. The expression of NRF2 downstream genes maintain the oxidative homeostasis and cell survival. Cancer cells tend to exhibit constitutive NRF2 activity through intrinsic oxidative stress and KEAP1 mutations, and therefore support tumor expansion and therapy resistance. Brusatol inhibits NRF2 by enhancing protein ubiquitination, resulting in the disrupted redox balance, cell death and tumor suppression

Back to article page